(Press-News.org) DURHAM, N.C. – Tirzepatide, a drug approved for diabetes and on the fast track for approval as a weight loss therapy, works through a unique ability to activate two different mechanisms the body uses to control insulin secretion and energy balance, Duke Health researchers report.
The finding, reported June 5 in the journal Nature Metabolism, is the first study to use cells from human donors to demonstrate how tirzepatide stimulates insulin secretion, an important action utilized by this drug to lower blood glucose in patients with type 2 diabetes.
“Understanding the potential of drugs that target more than one mechanism opens a whole new world of discovery for better weight-loss and diabetes drugs,” said senior author Jonathan Campbell, Ph.D., associate professor in the departments of Medicine and Pharmacology and Cancer Biology at Duke University School of Medicine, and member of the Duke Molecular Physiology Institute.
Tirzepatide is marketed under the brand name Mounjaro. It and similar therapies are known as receptor agonists, meaning they bind to a certain receptor in cells, triggering a specific action for that cell to carry out. There is a long history of diabetes therapies that target the glucagon-like peptide-1 (GLP-1) receptor.
For people with type 2 diabetes, these GLP-1-based drugs restore insulin production and lower blood glucose. The therapies also make people who take the medication feel full longer and reduce appetite, which leads to people dropping weight over time. This has made GLP-1 based therapies very attractive for the treatment of diabetes and obesity.
Tirzepatide is unique in this class of drugs, in that it targets not only the GLP-1 receptor, but also an additional receptor for the glucose-dependent insulinotropic polypeptide (GIP). In theory, this additional receptor gives the drug a broader range of activity inside the body.
However, the GIP receptor has historically been overlooked as a target for metabolic disease, with some people even proposing to block this receptor rather than activate it. This history fed speculation from some in the field that the activity of tirzepatide at the GIP receptor was not important, inferring that tirzepatide worked as a “super” GLP-1 receptor agonist.
Campbell and colleagues originally expected to find that most of the activity of tirzepatide was at the GLP-1 receptor. But in experiments using donated cadaver islet cells, they found that it was the GIP receptor that was indispensable for the insulin secretion that occurred when the islets were stimulated with tirzepatide.
They also found that tirzepatide stimulated the production of glucagon, another islet hormone. GIP stimulates glucagon secretion, while GLP-1 inhibits it. The finding that tirzepatide stimulates glucagon secretion is more evidence that this drug has important activity at the GIP receptor.
“Because our work shows that tirzepatide is a true multi-receptor agonist, and not just a super-GLP-1 receptor agonist, it validates the potential of using single molecules with activity at more than one receptor as a viable approach to treat metabolic disease,” Campbell said. “Extending these studies to the cell types that control appetite and body weight should be an important and exciting future direction.”
In addition to Campbell, study authors include Kimberley El, Jonathan D. Douros, Francis S. Willard, Aaron Novikoff, Ashot Sargsyan, Diego Perez-Tilve, David B. Wainscott, Bin Yang, Alex Chen, Donald Wothe, Callum Coupland, Mattias Tschöp, Brian Finan, David A. D’Alessio, Kyle W. Sloop, and Timo D Müller.
The study received funding support from the National Institutes of Diabetes and Digestive and Kidney Diseases (K01 DK132461, R01 DK123075, DK125353, DK046492), the European Research Council (no.695054), the German Research Foundation (DFG TRR296, TRR152, SFB1123 and GRK 2816/1), the German Center for Diabetes Research, the European Research Council (no.101044445), the Helmsley Charitable Trust Foundation, and investigator-initiated grants from Eli Lilly, Novo Nordisk, and Proteostasis.
Tirzepatide is manufactured by Eli Lilly and Company. The Campbell group receives funding for basic science from Novo Nordisk and Eli Lilly. Additional disclosures are acknowledged in the study.
###
END
CHICAGO – Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
Data from the study were presented today by Jason Westin, M.D., director of clinical research in the Department of Lymphoma and Myeloma, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and published concurrently in ...
Women have long searched for remedies for the bothersome hot flashes that often come with menopause.
In a novel investigation, researchers at UC San Francisco tested the benefits of continuously wearing a nitroglycerin patch – an established treatment for chest pain from coronary artery disease – for menopausal women experiencing at least seven hot flashes a day. Unlike most treatments for hot flashes that target brain mechanisms, nitroglycerin works on blood vessels throughout the body.
The results were mixed. While ...
The assembly of the volant bird body plan from the ancestral bulky dinosaurian condition is an enduring topic of evolutionary biology. The body plan of volant birds demonstrates a pronounced decrease in body size and proportionate elongation of the forelimbs. Given the scaling relationship between limb and body size, changes to the former were likely clouded by changes to the entire body size.
Since changes to individual limb elements provides the direct basis for natural selection, they are essential to comprehending branch- and lineage-specific evolutionary patterns across the transition from terrestrial to ...
How do today’s indigenous communities of South America trace back to the history of human migration and contact in the continent? An international team has worked to reconstruct the legacy of Chile’s largest indigenous community, the Mapuche, in a quest to strengthen their representation in the history of the continent. It appears the Mapuche long lived in relative isolation but do bear some influences from other populations of the Central Andes and the far south of Chile.
South America was the last continent ...
LA JOLLA, CALIF. – June 5, 2023 – Researchers at Sanford Burnham Prebys, collaborating with scientists from Eli Lilly and Company, have revealed the structure and function of a drug called LY3361237, which can reduce the harmful activity of the immune system to help treat autoimmune diseases. Their work laid the foundation for a new treatment that’s currently in a Phase 2 clinical trial for lupus, an autoimmune disease affecting multiple organs in the body. The study is published in Structure, a Cell Press journal.
The ...
FOR IMMEDIATE RELEASE
Johns Hopkins scientists have developed a method involving artificial intelligence to visualize and track changes in the strength of synapses — the connection points through which nerve cells in the brain communicate — in live animals. The technique, described in Nature Methods, should lead, the scientists say, to a better understanding of how such connections in human brains change with learning, aging, injury and disease.
“If you want to learn more about how an orchestra plays, you have to watch individual players over time, and this ...
Two new discoveries from the Dudley lab at UVA Cancer Center highlight the different roles of blood vessels in solid tumors – and the findings could help prevent breast cancer from spreading and enhance the effectiveness of one of the most important new cancer treatments in many years.
In one new scientific paper, researcher Andrew C. Dudley, PhD, and his team report that the effectiveness of immunotherapy drugs called immune check blockade is enhanced when blood vessels are targeted in a specific way. (Immunotherapy enhances the power of the immune system to fight cancer and other diseases.) In another paper, published ...
Awash in a rowed sea of its brethren, a corn leaf relegated to the lowest rung of its stem spends much of a June afternoon doused in shade cast by the higher-ups.
Then a gust begins pushing, pulling and twisting the waxy wings in concert, cracking a window to the fireball roiling 93 million miles away. It’s a prime, precious opportunity for photosynthesis to transform the sunlight into food. Unfortunately, the photosynthetic equivalent of a surge protector — one evolved to help plants mitigate damage driven by sudden spikes of high-intensity light — is slow to reset after so much time in the shade. The gust dissipates, the moment ...
Moving towards a more inclusive approach to medicine
Release of pangenome representing wide diversity of individuals ushers in new understanding of human biology and disease
The first human genome, which has served as the reference until now, was released approximately 20 years ago. It was a landmark accomplishment that had a huge impact on biomedical research and changed the way scientists study human biology. But it was based on just a few individuals and did not capture the full genetic diversity of the human population.
An important step forward for both biology and biomedical research
“Since ...
SAN ANTONIO — June 5, 2023 —Southwest Research Institute is expanding its flow meter research in collaboration with NYSEARCH, a nonprofit research and development organization for the gas industry, to address the impact of introducing hydrogen and natural gas blends into the residential and commercial energy mix. In the second phase of the program, SwRI will expand its research in measuring the energy content of blended gas to determine the accuracy of current flow meter technology for monitoring usage in homes.
Natural gas is widely used to power appliances and heat ...
